506 HYMOVIS™, A HEXADECYLAMIDE HYALURONAN DERIVATIVE (HYADD®4-G), INHIBITS GENE EXPRESSION CHANGES INDUCED BY INTERLEUKIN-lp IN CHONDROCYTES AND SYNOVIAL FIBROBLASTS DERIVED FROM OSTEOARTHRHIS PATIENTS - ResearchGatedoi:10.1016/S1063-4584(11)60533-5M. M. Smith...
A BREAKTHROUGH in the treatment of osteoarthritis (OA) knee pain, HYMOVIS® is helping active people everywhere write their own story about moving past pain and back to the things they love in life. If a simple, two-injection regimen for convenient and
The aim of the study was to evaluate the clinical efficacy and safety of HYMOVIS®(HYADD® 4), a hydrogel based on a hyaluronic acid derivative, in patients with symptomatic knee osteoarthritis Study design A retrospective observational study to evaluate the clinical efficacy and tolerability of...
HYADD 4 versus methylprednisolone acetate in symptomatic knee osteoarthritis: a single-Centre single blind prospective randomised controlled clinical study with 1-year follow-up. Clin Exp Rheumatol. 2016;34(5):857–63. 34. Henrotin Y, Bannuru RR, Malaise M, Ea H-K, Confavreux CB, Bentin ...
A novel slightly modified hyaluronic acid, HYADD4 (Hymovis;), has recently been tested in an ovine meniscectomy model of osteoarthritis, causing a reduction of vascularity and intimal hyperplasia, and an increase in the synthesis of high molecular weight HA by synovial fibroblasts (1). HYADD4 ...
HymovisSport activityViscosupplementationHip Osteoarthitis (OA) risk is sport-specific and depends on frequency, intensity, and type of mechanic stress the hip is subjected to. This retrospective observational study aims to investigate the safety and performance of Hymovis (HYADD-4) injection, a ...